Reports
Reports
The chronic fatigue syndrome treatment market reached a value of about USD 47.2 million in 2022 and is expected to grow at a CAGR of 4.2% during the forecast period of 2023-2031. With the growing incidences of mental disorders, the market is expected to reach about USD 68.2 million by 2031.
Chronic fatigue syndrome (CFS) is a medical condition that causes extreme fatigue or tiredness that does not go away with rest and cannot be explained by an underlying medical condition. CFS is also known as myalgic encephalomyelitis (ME) or systemic exertion intolerance disease (SEID).
CFS is a chronic illness with a wide range of symptoms like feeling extremely tired all the time, difficulty performing daily activities, taking a long time to recover from physical activity, sleeping problems, such as waking up frequently during the night, and problems with thinking, memory, and concentration. Because there is no specific test for CFS, it is diagnosed based on the symptoms and the exclusion of other conditions that could be causing the symptoms.
Due to the symptoms of CFS being similar to those of many common illnesses that usually improve on their own, a diagnosis of ME/CFS may be considered if one does not improve as quickly as expected.
While there is currently no cure for CFS, there are treatments that may help manage the condition. Some ME/CFS patients may benefit from the treatment of these symptoms, while others may not. Other strategies, such as learning new ways to manage activity, can be beneficial.
While the exact cause of this condition is unknown, other conditions like viruses, compromised immune system, stress, and/or hormonal imbalances might be responsible for triggering this condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Mode
Market Breakup by Distribution Channel
Market Breakup by End User
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Region
Nearly 2.5 million Americans of all ages, ethnicities, genders, and socioeconomic backgrounds suffer from chronic fatigue syndrome (CFS), however these groups suffer more than the others:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America dominates the chronic fatigue syndrome market due to changing lifestyles and rising healthcare expenditures, a well-developed healthcare sector, rising healthcare expenditures, large patient population, and government support for research and development. The region is likely to continue dominating the region in the forecast period as well due to the rising prevalence of the condition in the region.
Asia Pacific, on the other hand, is anticipated to witness significant growth in the chronic fatigue syndrome market due to a large patient population, rising prevalence of chronic fatigue syndrome, and the presence of a large opportunity in this market.
The major factors acting as restraints include the lack of awareness about the disease and a rise in the absence of information about the treatments and drug combinations available for the treatment of disease symptoms.
The condition cannot be managed with just one treatment since the symptoms are dynamic. Due to the constantly changing symptoms, the treatment methods also keep changing accordingly.
CFS can either cause or be a symptom of depression in many cases. Low-dose antidepressant therapy or a referral to a mental health provider may be required. If lifestyle changes do not result in a restful night's sleep, the doctor may advise taking a sleep aid. Pain relievers can also help you deal with aches and joint pain caused by CFS. If medication therapy is required, it must be tailored to the specific needs. There is no one-size-fits-all CFS treatment.
The report gives an in-depth analysis of the key players involved in the global chronic fatigue syndrome treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Mode |
|
Breakup by Distribution Channel |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Chronic Fatigue Syndrome Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Chronic Fatigue Syndrome Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.3 Europe Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.4 Asia-Pacific Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.5 Latin America Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.6 Middle East & Africa Chronic Fatigue Syndrome Epidemiology (2016-2031)
6 Global Chronic Fatigue Syndrome Treatment Market Overview
6.1 Global Chronic Fatigue Syndrome Treatment Market Historical Value (2016-2022)
6.2 Global Chronic Fatigue Syndrome Treatment Market Forecast Value (2023-2031)
7 Global Chronic Fatigue Syndrome Treatment Market Landscape
7.1 Chronic Fatigue Syndrome Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Chronic Fatigue Syndrome Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Mode
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by End User
8 Chronic Fatigue Syndrome Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Chronic Fatigue Syndrome Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Chronic Fatigue Syndrome Treatment Market Segmentation
11.1 Global Chronic Fatigue Syndrome Treatment Market by Type
11.1.1 Market Overview
11.1.2 Immune Enhancer and Antivirals
11.1.3 Sleep Enhancer
11.1.4 CNS Stimulants
11.1.5 Others
11.2 Global Chronic Fatigue Syndrome Treatment Market by Mode
11.2.1 Market Overview
11.2.2 Prescription Drugs
11.2.3 OTC Drugs
11.3 Global Chronic Fatigue Syndrome Treatment Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.4 Global Chronic Fatigue Syndrome Treatment Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Research Laboratories
11.5 Global Chronic Fatigue Syndrome Treatment Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Chronic Fatigue Syndrome Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Chronic Fatigue Syndrome Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Chronic Fatigue Syndrome Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Chronic Fatigue Syndrome Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Chronic Fatigue Syndrome Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Hemispherx Biopharma
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 GP Pharm
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Cadila Pharmaceuticals
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 USV
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Torrent Labs
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Goodfellow Pharma
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 F. Hoffmann-La Roche Ltd
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
24 Chronic Fatigue Syndrome Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The chronic fatigue syndrome treatment market attained a value of USD 47.2 million in 2022.
The market is likely to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 68.2 million by 2031.
The increase in research and government support for the development and awareness of chronic fatigue syndrome is a critical factor driving the market growth.
North America is the dominating region in the global market owing to the rising prevalence of the condition in the region.
The types of treatments for this condition include immune enhancer and antivirals, sleep enhancer, and CNS stimulants, among others.
The modes of condition can be categorized into prescription drugs and OTC Drugs.
The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
The end-user segments in the market include hospitals, clinics, and research laboratories.
Hemispherx Biopharma, GP Pharm, Cadila Pharmaceuticals, USV, Torrent Labs, Goodfellow Pharma, F. Hoffmann-La Roche Ltd, K-PAX Pharmaceuticals, CureME, and Dr Batra's are the leading companies in the market.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.